Nuclear transfer alters the DNA methylation status of specific genes in fertilized and parthenogenetically activated mouse embryonic stem cells

Stem Cells
Takafusa HikichiTeruhiko Wakayama

Abstract

Recent cloning technology has been demonstrated successfully using nuclear transfer (NT) techniques to generate embryonic stem (ES) cells. Mice can be cloned from adult somatic cells or ES cells by NT, and such cloned embryos can be used to establish new NT-ES cell lines. However, ES cells derived from parthenogenetic embryos show epigenetic disorders and low potential for normal differentiation unless used to produce subsequent generations of NT-ES lines. Thus, enucleated oocytes can initialize epigenetic modification, but the extent and efficacy of this remain unclear. In this study, our goal was to clarify why the contribution rate of ES cells derived from parthenogenetic embryos (pES) cells appears to improve after NT. We compared gene expression profiles between pES and NT-pES cell lines using DNA microarray analysis and allele-specific DNA methylation analysis. Although changes in expression level were observed for 4% of 34,967 genes, only 81 (0.2%) showed common changes across multiple cell lines. In particular, the expression level of a paternally expressed gene, U2af1-rs1, was significantly increased in all NT-pES cell lines investigated. The methylation status at the upstream differentially methylated region of U2af1-...Continue Reading

References

Mar 20, 1995·Analytical Biochemistry·A M RaizisJ P Jost
Jan 11, 1995·Nucleic Acids Research·I HatadaT Mukai
Dec 11, 1993·Nucleic Acids Research·I HatadaT Mukai
May 5, 1997·FEBS Letters·M OkabeY Nishimune
Mar 10, 2001·Molecular Reproduction and Development·T Wakayama, R Yanagimachi
Apr 18, 2001·The Journal of Biological Chemistry·Y SotomaruT Kono
May 23, 2002·Genes & Development·Michele BoianiK John McLaughlin
Sep 18, 2002·Proceedings of the National Academy of Sciences of the United States of America·David HumpherysRudolf Jaenisch
Dec 20, 2002·Developmental Biology·Hiroshi SuemizuMinoru S H Ko
May 16, 2003·Biology of Reproduction·Mellissa R W MannMarisa S Bartolomei
Jun 13, 2003·Biology of Reproduction·Kimiko InoueAtsuo Ogura
Apr 23, 2004·Nature·Tomohiro KonoHidehiko Ogawa
Aug 13, 2004·Proceedings of the National Academy of Sciences of the United States of America·Robert H BlellochRudolf Jaenisch
Dec 25, 2004·Proceedings of the National Academy of Sciences of the United States of America·Sayaka WakayamaTeruhiko Wakayama
Aug 27, 2005·Biology of Reproduction·Takashi KohdaFumitoshi Ishino
Jan 19, 2006·Proceedings of the National Academy of Sciences of the United States of America·Tobias BrambrinkRudolf Jaenisch
Jul 29, 2006·Development, Growth & Differentiation·Noelia AndolloJuan M Aréchaga
Aug 4, 2006·Reproduction : the Official Journal of the Society for the Study of Fertility·T AmanoH Suzuki
Feb 28, 2007·Nature Genetics·Xiangzhong YangTeruhiko Wakayama
Apr 5, 2007·Nature Protocols·Satoshi KishigamiTeruhiko Wakayama
Aug 21, 2007·Nature Biotechnology·Manabu KawaharaTomohiro Kono

❮ Previous
Next ❯

Citations

Mar 6, 2010·The Journal of Reproduction and Development·Nguyen Van ThuanTeruhiko Wakayama
Jul 31, 2009·Science in China. Series C, Life Sciences·Jie HaoQi Zhou
Jul 31, 2009·Differentiation; Research in Biological Diversity·Shengchang HuangShaorong Gao
Sep 11, 2008·Genesis : the Journal of Genetics and Development·Eiji MizutaniTeruhiko Wakayama

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Fate Conversion By mRNA

mRNA-based technology is being studied as a potential technology that could be used to reprogram cell fate. This technique provides the potential to generate safe reprogrammed cells that can be used for clinical applications. Here is the latest research on cell fate conversion by mRNA.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.